Calcium Phosphate Nanoparticles for Transcutaneous Vaccine Delivery
The main objective of this study was to investigate the potential of calcium phosphate (CAP) nanoparticles for transcutaneous vaccine delivery. CAP nanoparticles were prepared by nanoprecipitation method followed by sequential adsorption of sugars and ovalbumin. Nanoparticles were characterized
using dynamic light scattering, XRD, ATR-FTIR, and microscopy methods. In-vitro release of ovalbumin from nanoparticles was studied in phosphate buffer (pH 7.4). In-vivo immunization studies were carried out in Balb/C mice. The size and zeta potential of ovalbumin-sugar adsorbed
CAP nanoparticles was 350 ± 22.5 nm and –12.93 ± 1.02 mV respectively. Around 60% ovalbumin was released from nanoparticles within 24 hrs. To test the feasibility for transcutaneous vaccine delivery, the nanoparticles were applied in mice after removing the stratum corneum
by tape-stripping. In the positive control group, the nanoparticles were administered by intradermal injection. Ovalbumin-sugar coated CAP nanoparticles showed significantly higher antibody titers (Total IgG and IgG1) compared to ovalbumin alone. IgG2a antibodies were only seen with intradermal
injection. Both topical and intradermal treatment groups showed splenocyte proliferation when re-stimulated with ovalbumin. The results from this study demonstrate the potential of using CAP nanoparticles for transcutaneous vaccine delivery.
Keywords: ADJUVANT; CAP NANOPARTICLES; TAPE STRIPPING; TRANSCUTANEOUS VACCINATION
Document Type: Research Article
Publication date: 01 January 2013
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content